AIB301 / AIBIOS - LARVOL DELTA

IBios, which discovers the mechanism that acts on intestinal immunomodulation and develops immunopharmaceuticals, raises 770 million yen [Google translation] (TechCrunch) - "...AIBIOS announced that it would raise a total of approximately 770 million yen through a third-party allotment of capital. Underwriters are SBI Investment Co., Ltd., a lead investor, Beyond Next Ventures, an existing shareholder, and Axil Capital...AIBIOS focuses on the balance of the immune system in the intestinal tract, and is a new drug candidate AIB-301 for inflammatory bowel disease (IBD) that develops in the intestinal mucosa that works at the forefront of biological defense."

Financing • Immunology • Inflammatory Bowel Disease